menu
    • menu
    [{"orgOrder":0,"company":"old Sano","sponsor":"Koneksa","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tolebrutinib","moa":"||BTK","graph1":"Neurology","graph2":"Phase III","graph3":"old Sano","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"old Sano \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"old Sano \/ old Sano"},{"orgOrder":0,"company":"old Sano","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tolebrutinib","moa":"||BTK","graph1":"Neurology","graph2":"Phase III","graph3":"old Sano","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"old Sano \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"old Sano \/ old Sano"}]

    Find Clinical Drug Pipeline Developments & Deals by old Sano

    Menu

    old Sano

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            old Sano

                            France arrow
                            EPSC
                            Not Confirmed

                            old Sano

                            France arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolebrutinib,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Terran Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets

                            Details : Terran plans to quickly advance the development of the lead SAR442168 and other assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 21, 2022

                            Lead Product(s) : Tolebrutinib,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Terran Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            old Sano

                            France arrow
                            EPSC
                            Not Confirmed

                            old Sano

                            France arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolebrutinib,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Koneksa

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi

                            Details : Koneksa's work with Sanofi will support the investigation of tolebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, which is an oral, brain-penetrant, selective small molecule currently in Phase III trial.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 11, 2021

                            Lead Product(s) : Tolebrutinib,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Koneksa

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth